BR112019001826A2 - composição de liberação prolongada compreendendo tolcapone micronizada - Google Patents

composição de liberação prolongada compreendendo tolcapone micronizada

Info

Publication number
BR112019001826A2
BR112019001826A2 BR112019001826-3A BR112019001826A BR112019001826A2 BR 112019001826 A2 BR112019001826 A2 BR 112019001826A2 BR 112019001826 A BR112019001826 A BR 112019001826A BR 112019001826 A2 BR112019001826 A2 BR 112019001826A2
Authority
BR
Brazil
Prior art keywords
tablet
extended release
release composition
transthyretin
prevention
Prior art date
Application number
BR112019001826-3A
Other languages
English (en)
Inventor
Nardi Ricart Anna
María SUÑÉ NEGRE Josep
Reig Bolaño Núria
Insa Boronat Raúl
Huertas Gambín Oscar
Esteva Gras Santiago
Pericot Mohr Gal.La
Original Assignee
Som Innovation Biotech, S.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Som Innovation Biotech, S.L. filed Critical Som Innovation Biotech, S.L.
Publication of BR112019001826A2 publication Critical patent/BR112019001826A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção se refere a comprimidos de liberação prolongada compreendendo tolcapone micronizada, um retardante de liberação e um ligante, ao referido comprimido para utilização na prevenção e / ou tratamento de uma amiloidose associada a transtirretina, a um método para a prevenção e / ou tratamento de um amiloidose associada a transtirretina compreendendo a administração a um indivíduo em necessitado de uma quantidade eficaz do referido comprimido, a uma composição farmacêutica na forma do referido comprimido que é utilizada na prevenção e / ou tratamento de uma amiloidose associada a transtirretina e a um processo para a fabricação do referido comprimido.
BR112019001826-3A 2016-07-29 2017-07-28 composição de liberação prolongada compreendendo tolcapone micronizada BR112019001826A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382372.7A EP3275433A1 (en) 2016-07-29 2016-07-29 Sustained release composition comprising micronized tolcapone
EP16382372.7 2016-07-29
PCT/EP2017/069168 WO2018019997A1 (en) 2016-07-29 2017-07-28 Sustained release composition comprising micronized tolcapone

Publications (1)

Publication Number Publication Date
BR112019001826A2 true BR112019001826A2 (pt) 2019-05-07

Family

ID=56571284

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019001826-3A BR112019001826A2 (pt) 2016-07-29 2017-07-28 composição de liberação prolongada compreendendo tolcapone micronizada

Country Status (14)

Country Link
US (1) US11883538B2 (pt)
EP (2) EP3275433A1 (pt)
JP (1) JP7047236B2 (pt)
KR (1) KR102484678B1 (pt)
CN (1) CN109789100A (pt)
AU (1) AU2017303333B2 (pt)
BR (1) BR112019001826A2 (pt)
CA (1) CA3032211A1 (pt)
DK (1) DK3490535T3 (pt)
ES (1) ES2891355T3 (pt)
MX (1) MX2019001190A (pt)
PT (1) PT3490535T (pt)
RU (1) RU2750670C2 (pt)
WO (1) WO2018019997A1 (pt)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
CN1129429C (zh) * 1996-05-20 2003-12-03 G·D·瑟尔公司 钾、钠和三羟甲基氨基甲烷噁丙嗪盐药物配方
US6299906B1 (en) * 1998-04-09 2001-10-09 Hoffmann-La Roche Inc. Process for making submicron particles
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CA2510319A1 (en) * 2002-12-20 2004-07-15 Thomas J. Smith High pressure compaction for pharmaceutical formulations
CA2611114C (en) * 2005-06-08 2014-09-23 Orion Corporation An entacapone-containing oral dosage form
US20100112053A1 (en) * 2007-01-15 2010-05-06 Kissei Pharmaceutical Co., Ltd. Gastric retention-type sustained-release levodopa preparation
HUE037005T2 (hu) 2010-11-15 2018-08-28 Neuroderm Ltd L-dopának, dopa dekarboxiláz inhibitoroknak, katechol-O-metil transzferáz inhibitoroknak és ezekhez szolgáló kompozícióknak folyamatos bevezetése
EP2770988B1 (en) 2011-10-24 2016-07-20 Som Innovation Biotech S.L. New therapy for transthyretin-associated amyloidosis
US20130195973A1 (en) * 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
JP6472391B2 (ja) * 2013-03-13 2019-02-20 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ パーキンソン病の治療方法
CN105873631B (zh) * 2013-11-05 2021-06-18 辛纳吉勒公司 经由口腔进行连续药物递送的装置和方法
DK3782617T3 (da) * 2014-09-04 2024-03-04 Lobsor Pharmaceuticals Ab Farmaceutiske gelsammensætninger omfattende levodopa, carbidopa og entacapon

Also Published As

Publication number Publication date
CA3032211A1 (en) 2018-02-01
AU2017303333B2 (en) 2023-03-30
EP3275433A1 (en) 2018-01-31
RU2019103647A3 (pt) 2020-10-12
WO2018019997A1 (en) 2018-02-01
RU2019103647A (ru) 2020-08-28
KR102484678B1 (ko) 2023-01-03
AU2017303333A1 (en) 2019-03-14
CN109789100A (zh) 2019-05-21
ES2891355T3 (es) 2022-01-27
US11883538B2 (en) 2024-01-30
JP2019523305A (ja) 2019-08-22
JP7047236B2 (ja) 2022-04-05
PT3490535T (pt) 2021-09-30
RU2750670C2 (ru) 2021-06-30
EP3490535A1 (en) 2019-06-05
EP3490535B1 (en) 2021-07-14
KR20190034563A (ko) 2019-04-02
US20190167596A1 (en) 2019-06-06
DK3490535T3 (da) 2021-10-04
MX2019001190A (es) 2019-09-06

Similar Documents

Publication Publication Date Title
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
NI201600071A (es) Compuestos de inhibidor de autotaxina
CR20150326A (es) Inhibidores de autotaxina
CR20160275A (es) Derivados del sulphamoylpyrrolamide y uso como medicamento para el tratamiento de la hepatitis b
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
BR112017003546A2 (pt) amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112017011644A2 (pt) métodos e composições de ativação da ligase parkina
BR112017010440A2 (pt) administração sublingual de riluzol
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
BR112015011430A2 (pt) composição para liberação imediata e prolongada
BR112017010423A2 (pt) formulação sublingual de riluzol
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112018000739A2 (pt) composições farmacêuticas contendo celecoxib e tramadol
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CL2019000625A1 (es) Combinación de agonistas de fxr.
BR112017017729A2 (pt) forma de dosagem oral de liberação controlada de agonista de receptor gaba
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
BR112015022513A2 (pt) produto e método para tratamento de diarreia
BR112016026470A8 (pt) composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]